Allen Feldman, MD, Mph, MBA
About Allen Feldman, MD, Mph, MBA
Allen Feldman, MD, MPH, MBA, is the Vice President of Worldwide Patient Safety, Hematology (Oncology) at Bristol Myers Squibb, with extensive experience in drug safety and pharmacovigilance.
Title
Allen Feldman is the Vice President of Worldwide Patient Safety for Hematology (Oncology) at Bristol Myers Squibb. He assumed this role on November 1, 2019.
Current Position at Bristol Myers Squibb
At Bristol Myers Squibb, Allen Feldman oversees global patient safety within the hematology (oncology) division. His responsibilities include strategic clinical safety, safety operations, risk management, and pharmacoepidemiology for hematology and oncology therapeutics.
Previous Experience at Celgene
Before joining Bristol Myers Squibb, Allen Feldman was the Vice President of Global Drug Safety, Hematology/Oncology at Celgene from 2016 to 2019. In this role, he was responsible for overseeing drug safety and pharmacovigilance from early development through post-marketing for hematology and oncology drugs.
Previous Tenure at Daiichi Sankyo
From 2004 to 2016, Allen Feldman served as Vice President, Clinical Safety and Pharmacovigilance at Daiichi Sankyo. He led initiatives focused on clinical safety and was significantly involved in safety operations, risk management, and patient safety across various therapeutic areas, including cardiovascular diseases, diabetes, and infectious diseases.
Education and Expertise
Allen Feldman holds an MD from the State University of New York Upstate Medical University, an MPH from Johns Hopkins Bloomberg School of Public Health, and an MBA from New York University, Stern School of Business. He also completed a Medical Staff Fellowship in the Division of Cancer Prevention and Control at the National Cancer Institute, National Institutes of Health. His educational background complements his extensive experience in therapeutic areas such as hematology, oncology, cardiovascular diseases, diabetes, and infectious diseases.